E.MollerM.Le DousN.JensenA
"It just so happens to benefit the consumers that might want smaller portions that are on GLP-1 medications, and we have a lot of options like that in all of our menus," Cardenas said on the company's earnings conference call in December
Furthermore, enduring weight-related stigma, skepticism about the long-term safety and effectiveness of these agents, and concerns about the potential for off-label or inappropriate use present additional obstacles
According to Grand View Research, specifically for GLP-1 weight-loss, the market size in 2025 is about $20.86 billion, expected to grow to $48.84 billion by 2030, with a CAGR of ~18.5%
1 These products feature portion-controlled options, such as grain bowls, mini flatbread pizzas with cauliflower crust, and high-protein sandwich melts designed to support the nutritional needs of individuals consuming smaller portions due to medication-induced appetite suppression